PowerPoint Presentation (PDF) - Perfusion.com

More documents

Recommendations

Info

Warning Cardiac Therapy The safety and effectiveness of Argatroban for cardiac indications outside of percutaneous coronary intervention ti (PCI) in patients with HIT have not been established.
Case Report May 23, 2008
Page 1 and 2: Aortic Valve Replacement in the Set
Page 3 and 4: Pathogenesis of HIT • In select p
Page 5 and 6: Complications of HIT • Deep vein
Page 8: • Synthetic • 526.66 daltons
Page 13 and 14: Patient Information • BSA 2.00
Page 15 and 16: • 3/16 inch line for CO 2 infusio
Page 17 and 18: Perfusion Circuit
Page 19 and 20: Prime • 2PRBC’s • 0.8 Liters
Page 21 and 22: Calculating Sieving Coefficient Cal
Page 23 and 24: Dosing Considerations • Drug is m
Page 25 and 26: Monitoring: TEG Symbols • R - Ini
Page 27 and 28: On CPB • Loading Dose given @ 140
Page 29 and 30: • I.V. adjustment to 3.0 mcg/Kg/m
Page 31 and 32: Argatroban Procedure
Page 33 and 34: Revaluation • Net Clot Strength i
Page 35 and 36: 30 min Post Argatroban Bolus • I-
Page 37 and 38: CPB • Total Bypass 98 minutes •
Page 39 and 40: Time ACT ACT2 RTEG Angle MA G Hct U
Page 41 and 42: • I-Stat ACT 633 / 767 ICU TEG
Page 43 and 44: • I-Stat TEG >1000 / 767 ICU TEG
Page 45 and 46: Concluding Thoughts • I-Stat ACT

PowerPoint Presentation (PDF) - Perfusion.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?